Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Werewolf Therapeutics, Inc. Common Stock

HOWL

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

Last trade $0.9848
Day change -$0.006 (-0.61%)
Day range $0.948 – $1.00
Volume 532,092
Market cap $48M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$48.11M
Price / earnings
—
Price / book
2.95×
Price / sales
2.29×
EV / sales
1.24×
EV / EBITDA
-0.95×

Profitability

Earnings per share
-$0.71
Return on assets
-143.3%
Return on equity
-212.45%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.91×
Quick ratio
2.91×
Cash ratio
2.8×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$30.15M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HOWL, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$21M$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$21M$0$0$0$0$0$0$0
Selling, general and administrative$7.68M$5.09M$2.49M$4.09M$4.4M$4.87M$4.62M$4.6M
Research and development$6.16M$8.18M$6.93M$11.63M$13.14M$13.12M$15.73M$12.53M
Total operating expenses$13.84M$13.27M$9.42M$15.73M$17.54M$17.99M$20.35M$17.12M
Operating income$7.16M-$13.27M-$9.42M-$15.73M-$17.54M-$17.99M-$20.35M-$17.12M
Interest expense-$475K-$1.37M-$1.37M-$1.34M-$1.3M-$1.26M-$1.27M-$1.24M
Income before taxes$3.67M-$13.53M-$8.38M-$16.37M-$17.98M-$18.09M-$20.4M-$16.67M
Income taxes$0$0$0$0$0$0$0$0
Net income$3.67M-$13.53M-$8.38M-$16.37M-$17.98M-$18.09M-$20.4M-$16.67M
Net income attributable to common shareholders$3.67M-$13.53M-$8.38M-$16.37M-$17.98M-$18.09M-$20.4M-$16.67M
EBITDA$9.61M-$12.87M-$9.02M-$15.32M-$17.14M-$17.57M-$19.91M-$16.67M
Basic earnings per share$0.08-$0.28-$0.17-$0.36-$0.40-$0.40-$0.46-$0.38
Diluted earnings per share$0.08-$0.28-$0.16-$0.36-$0.40-$0.40-$0.44-$0.38

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Krystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development.

Zacks Investment Research

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy) rating based on upward trends in earnings estimates. The company's consensus estimate has increased 17.6% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation.

Zacks Investment Research

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027.

Zacks Investment Research

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

Mirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million.

Zacks Investment Research

New Strong Buy Stocks for October 9th

Zacks has added five stocks to its Strong Buy list based on positive earnings estimate revisions over the last 60 days. The stocks include Lumentum Holdings (optical/photonic products), Werewolf Therapeutics (cancer biopharmaceutical), Perion Network (digital advertising), Goldman Sachs BDC (business development), and Griffon Corporation (diversified management).

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.